If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery time. The Evaluate Vantage team has produced its round up of the investment and financial side of the industry and the results make for interesting – if sobering – reading.
Register now to receive your copy.
Share
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the ...
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...
2023 is a year that many in the pharma market will be happy to see the back of, and the digital health ecosystem is no exception. Some of this can ...
